Tagged with B

Saudi Arabia Founded in 2016, the groundbreaking healthtech start-up Aumet has set out to digitize the procurement cycle within the pharmaceutical sector with its AI-enabled business-to-business healthcare platform. Co-founder and managing director for Saudi Arabia, Mohamed Mazen Batterjee, explains the strong foothold the company has established in the region and how its…

India President of India’s Diabetes & Obesity Centre, Dr Brij Mohan has an extensive background in the field of diabetes, having served on the board of Diabetes India and as president of the Research Society for the Study of Diabetes in India (RSSDI). He outlines the significant diabetes burden in a…

India India’s National Chemical Laboratory (NCL), one of the most well-established labs in the wider Council of Scientific and Industrial Research (CSIR) network, has made some major contributions to improving the country’s manufacturing processes for pharmaceutical intermediates and APIs. Director Dr Ashish Lele outlines the approaches the lab is pursuing, such…

China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…

Saudi Arabia Ismail Shehada explains his decision to join leading Saudi firm Tabuk Pharmaceuticals, influenced by its potential for growth and strategic transformation in alignment with Saudi Vision 2030. He outlines the need to transition from consultancy-driven strategies to business implementation, aligning with the national agenda and achieving market leadership.   As…

India Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He also explains how the 2023 National Medical Device Policy marks a significant shift towards recognizing the distinct needs of the…

Europe PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient advocates, industry representatives, and service providers in attendance were treated to a three-day buffet of engaging panels and townhalls with…

Global Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for the organisation and must now lay out Gavi’s strategic plan for 2026 to 2030, as well as convince its partners…

USA Online pharmacies have still not captured a large share of the fragmented US pharma market, but Eli Lilly’s partnership with Amazon after a direct-sale initiative of its own may serve to shake up the establishment and show what a direct-to-consumer model can offer.   Eliminating the Middleman, or Not Amazon…

Saudi Arabia Halal pharmaceuticals, or medicines produced according to Islamic dietary laws, presented a global market worth some USD 100 billion in 2019, yet much of halal pharmaceuticals’ potential remains untapped. In conversation with PharmaBoardroom, Mazen M. Hassanain, co-founder and managing director of SaudiVax, a pioneer in halal vaccines, discusses the development…

USA The COVID-19 pandemic looked like a turning point for vaccines, but while R&D has made tremendous strides with ground-breaking platform technologies and mRNA, vaccines continue to attract fewer investments than areas such as oncology. As panel members at the “Reviewing Vaccine Pipeline Breakthroughs and Barriers” session during BIO’s recent CEO…

Germany The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion into the US; the antibody-drug conjugate (ADC) specialist Tubulis’ series B2 financing, and Novartis’ deal with biotech MorphoSys.   Germany’s…